Squamous cell carcinoma

Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Retrieved on: 
Monday, December 12, 2022
Squamous cell carcinoma, FLT3, Lymphatic system, Dana–Farber Cancer Institute, Venetoclax, Cancer, Disease, BTK, Patient, COVID-19, AML, MDS, Patent, Risk, Form 10-K, Azacitidine, B-cell lymphoma, MYD88, Myelodysplastic syndrome, Multimedia, Toxic leukoencephalopathy, NCI, Security (finance), Toll-like receptor, Webcast, Food, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Genentech, Roche, U2AF1, Form, Marketing, Mutation, Therapy, IL-1R, CRS, Biomarker, Research, CRADA, FDA, BCC, Safety, Hoffmann-La Roche, Acute myeloid leukemia, NF, TLR, Pharmaceutical industry, SF3B1, Curie Institute (Paris), Vismodegib, IRAK4

LEXINGTON, Mass., Dec. 12, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced positive updated clinical data from the ongoing open label Phase 1a dose escalation study of emavusertib (CA-4948), a novel, small molecule IRAK-4 inhibitor, as a monotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (hrMDS) in both targeted and non-targeted populations. Patients in a targeted population are those with disease harboring U2AF1, SF3B1 (collectively "spliceosome") or FLT3 mutations. The company also announced positive initial data of emavusertib in combination with venetoclax in patients with AML or hrMDS that enrolled in the combination phase (Phase 1b) of the TakeAim Leukemia study prior to the partial clinical hold placed in April 2022.

Key Points: 
  • This represents 11 additional patients treated in targeted monotherapy populations and 13 additional patients in the non-targeted monotherapy population.
  • In addition to the monotherapy data, there are 4 patients with AML/hrMDS who have been treated with emavusertib in combination with venetoclax.
  • Previous data presented by Curis highlighted preliminary efficacy data of emavusertib in R/R AML/MDS patients whose disease is characterized by spliceosome or FLT3 mutation.
  • TakeAim Leukemia Study (NCT04278768) - This study is only enrolling in the monotherapy dose finding phase (phase 1a) of the study.

Extensive Stage Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032

Retrieved on: 
Thursday, December 8, 2022
Standard of care, Benchmarking, Durvalumab, Jazz Pharmaceuticals, Research report, Commercial, Lurbinectedin, Patient, Prevalence, Clinical, Carboplatin, Etoposide, Lung cancer, AstraZeneca, Disease, Platinum, Cisplatin, Survival, Squamous cell carcinoma, Region, Organization, Pharmaceutical industry, Uranium, Fine chemical, Vaccine

View original content:https://www.prnewswire.com/news-releases/extensive-stage-small-cell-lung...

Key Points: 
  • Extensive stage small cell lung cancer is extremely aggressive sub-type of small cell lung cancer.Small cell lung itself is a sub-type of lung cancer which accounts for less than 20% cases.
  • The prevalence of extensive stage small lung cancer is estimated to increase in five of the seven major markets included in the study.
  • Since, the introduction of immune checkpoint inhibitors to the extensive stage small cell lung cancer treatment, the competition in the global extensive stage small cell lung cancer market has significantly increased.F.
  • Competitive Strategy: Key players in the global extensive stage small cell lung cancer market were analyzed and profiled in the study, who have commercially available treatment for extensive stage small cell lung cancer.Moreover, a detailed competitive benchmarking of the players operating in the global extensive stage small cell lung cancer market has been included to help the reader understand how players stand against each other, presenting a clear market landscape.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, December 5, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Food, Biotechnology, Aurora, Regulation of tobacco by the U.S. Food and Drug Administration, Capecitabine, Financial compensation, Royal commission, Patient, Employment, Breast cancer, FDA, Puma Biotechnology, Tablet, European Commission, Squamous cell carcinoma, Pharmaceutical industry

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 3, 2022, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering 20,625 shares of Puma common stock to three new non-executive employees.

Key Points: 
  • Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 3, 2022, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering 20,625 shares of Puma common stock to three new non-executive employees.
  • The awards were granted under Pumas 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma.
  • The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.

Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of Wide-Field Optical Coherence Tomography (WF-OCT) in Head and Neck Surgeries

Retrieved on: 
Monday, December 5, 2022
Technology, Health, Radiology, Oncology, Health Technology, Medical Devices, Research, Artificial Intelligence, Surgery, Science, Clinical Trials, SCC, Recurrence, TSX Venture Exchange, Pharynx, OTC, JAMA, Breast cancer, Medical imaging, Cancer Prevention and Research Institute of Texas, MD, Analysis, Research institute, MRI, Perimeter, Head, Patient, Cancer prevention, Research, DDS, Breast Cancer Awareness Month, Progression-free survival, Professor, FDA, Pathology, FSE, News, University, Radiation, Tissue, Public expenditure, Tax, Optical coherence tomography, SEDAR, Hope, Legislation, Squamous cell carcinoma, Risk, Dentistry, Medicine

Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (Perimeter or the Company) announced the publication of a peer-reviewed research article in JAMA OtolaryngologyHead and Neck Surgery.

Key Points: 
  • Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (Perimeter or the Company) announced the publication of a peer-reviewed research article in JAMA OtolaryngologyHead and Neck Surgery.
  • The studys findings validate the further exploration of the use of Perimeters wide-field Optical Coherence Tomography (WF-OCT) technology to visualize margins during head and neck surgeries.
  • Our research findings suggest that wide-field OCT may be a promising adjunct imaging modality for intraoperative visualization in head and neck surgery, especially at deep margins.
  • Jeremy Sobotta, Perimeters Chief Executive Officer commented, This publication further supports the potential use of our flagship Perimeter S-Series OCT medical imaging technology across several tissue types, including head and neck surgery.

Global Lung Cancer Screening Software Market Report 2022: Growing Awareness about Screening Programs Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022
Software, Technology, Health, Oncology, Porter's five forces analysis, COVID-19, SWOT, Growth, Geography, Investment, Observation, Ansoff Matrix, Midsayap Diagnostic Center and Hospital, Hospital, Risk, Market development, Squamous cell carcinoma, Medical imaging, Medical device, Retail, Risk management

The Global Lung Cancer Screening Software Market is segmented based on Cancer Type, Diagnosis Type, End-Users, and Geography.

Key Points: 
  • The Global Lung Cancer Screening Software Market is segmented based on Cancer Type, Diagnosis Type, End-Users, and Geography.
  • By Cancer Type, the market is classified into Non-Small Cell Lung Cancer, and Small Cell Lung Cancer.
  • The report presents a detailed Ansoff matrix analysis for the Global Lung Cancer Screening Software Market.
  • The report offers a comprehensive evaluation of the Global Lung Cancer Screening Software Market.

Genprex to Present at Upcoming December Investor Conference

Retrieved on: 
Friday, December 2, 2022
NSCLC, PDX1, Type 2, COVID-19, Insulin, MAF (gene), Human, Intellectual property, Pancreas, Tumor suppressor gene, Type 1, Diabetes, Large-cell lung carcinoma, Immune system, Cancer, Conference, Squamous cell carcinoma, Annual report, Risk, Growth, Q&A, Food, Food and Drug Administration Amendments Act of 2007, AAV, Protein, Autoimmunity, Patient, Security (finance), Gene, General counsel, Uncertainty, Pharmaceutical industry, Audit

AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company's gene therapies for cancer and diabetes at the following investor conference in December 2022.

Key Points: 
  • Ms. Vaczy will be available for Q&A following the presentation and for in-person one-on-one meetings with investors at the RHK Disruptive Growth Conference.
  • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
  • Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
  • You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all.

60th ANNUAL AUA AWARD WINNERS ANNOUNCED

Retrieved on: 
Thursday, December 1, 2022
American Urological Association, Science, ACGME, Diversity, Journal, Public policy, Prostate cancer, Film, Doctor of Philosophy, Art, MS, Health, Patient, FAAP, Education, Television, Medicine, Bladder cancer, Pelvic pain, Distinguished Service to Music Medal, Sculpture, Hugh H. Young, AUA, Diagnosis, William P. Didusch Center for Urologic History, Squamous cell carcinoma, Urology, Incontinence, Health policy, Inflammation, Prostate, Research, MPH, Culture, Pediatric urology, Andrology, FRCSC, MBA, Society, CPA Donald O. Hebb Award for Distinguished Contributions to Psychology as a Science, Annual general meeting, Gold, ABU, Quality of life, Photography, Ukrainians, Dentistry, Pharmaceutical industry, Management, Medical imaging, MD

BALTIMORE, Dec. 1, 2022 /PRNewswire/ -- The American Urological Association (AUA) announced today the list of 2023 award recipients. The winners will be recognized at the Association's Annual Meeting in Chicago, Illinois, next April marking the 60th anniversary of the awards program. The ceremony will celebrate physician researchers and educators for their contributions to the field of medicine, the specialty of urology and the AUA. 

Key Points: 
  • The winners will be recognized at the Association's Annual Meeting in Chicago, Illinois, next April marking the 60th anniversary of the awards program.
  • Lifetime Achievement Award: The Lifetime Achievement Award is presented annually to an individual for outstanding contributions to advance the mission and goals of the AUA.
  • Diversity & Inclusion Award: The Diversity & Inclusion Award is presented annually to an AUA member for outstanding impact on urologic diversity.
  • Gold-Headed Cane Award: The Gold-Headed Cane Award is presented to a senior urologist distinguished by outstanding contributions to the profession and to the AUA.

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Thursday, December 1, 2022
MSD, Merck Sharp & Dohme Federal Credit Union, Patient, Immune system, Head, Merck & Co., Lung, RECIST, Large-cell lung carcinoma, Squamous cell carcinoma, Therapy, Melanoma, CD137, Tumor microenvironment, PRS, Neoplasm, Mesothelioma, Cancer, Neck, Natural killer T cell, Immunoglobulin G, Medical imaging, Pharmaceutical industry, Vaccine, Compass, Merck

Patients enrolled in the study will be treated with CTX-471 in combination with KEYTRUDA with the goal of restoring response.

Key Points: 
  • Patients enrolled in the study will be treated with CTX-471 in combination with KEYTRUDA with the goal of restoring response.
  • We are very pleased to be making progress on our CTX-471 clinical program with dosing of the first patient in the combination arm with KEYTRUDA, said Thomas Schuetz, M.D., Ph.D., Chief Executive Officer and Scientific Founder of Compass.
  • CTX-471 has completed a Phase 1 dose escalation and cohort expansion study, where it was shown to be well-tolerated.
  • Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases.

SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Model

Retrieved on: 
Thursday, December 1, 2022
NCI, COVID-19, BRCA, PARP, Drug, ATR, DNA repair, DNA, Cancer, Squamous cell carcinoma, SCLC, Patient, Toxicity, Annual report, SCL, CDK9, MD, Drug development, Olaparib, Senior, SLS, Memorial Sloan Kettering Cancer Center, Mouse, WT1, Therapy, GPS, DDR, Pharmaceutical industry, Greater China

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from a preclinical in vivo study for its highly selective CDK9 inhibitor, GFH009, that demonstrate robust inhibition of tumor growth in a mouse xenograft model of small cell lung cancer (SCLC).

Key Points: 
  • GFH009 treated mice exhibited a 40.4% decrease in mean tumor growth compared to the control group in this very aggressive cancer model which had a tenfold increase in average tumor volume over 20 days.
  • Strongest effects were observed with GFH009 in combination with olaparib, with mean tumor growth decreased by 72.3%.
  • Treatment with olaparib alone resulted in a 30.2% mean decrease in tumor growth.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.

Actinic Keratosis Treatment Global Market Report 2022: Future Pipeline Medications and Further Use of Combination Therapy Promise Growth Moving Forward - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Health, Pharmaceutical, Marketing, S.A, Growth, Revenue, Diagnosis, ISCC, III, Prevalence, Topical medication, Squamous cell carcinoma, Drug class, Malignancy, USD, Disease, Neck, Therapy, Extremities, Pharmaceutical industry, Coal, Tirbanibulin

The global actinic keratosis treatment market size is anticipated to reach USD 8.93 billion by 2030., expanding at a CAGR of 4.1% from 2022 to 2030.

Key Points: 
  • The global actinic keratosis treatment market size is anticipated to reach USD 8.93 billion by 2030., expanding at a CAGR of 4.1% from 2022 to 2030.
  • The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment.
  • Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.
  • In addition, future pipeline medications and the increased use of combination therapy are key market drivers.